Identifying new inhibitors for cancer-related enzymes PLCγ1 and PLCγ2
Official title: Primary screening and hit follow up to identify the first selective inhibitors of PLC?1 and PLC?2
Funded at Purdue University · NIH-11014244 · Data updated 2026-11-12
This study is looking for new ways to block certain enzymes that are involved in cancer, using a special tool to quickly test a lot of different compounds, with the hope of finding new treatments for cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $572,254 |
| NIH project number | 1R01CA295436-01 |
| Project ID | NIH-11014244 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers associated with the dysfunction of PLCγ1 and PLCγ2, such as certain types of leukemia.
✕Less likely to help
Patients with cancers not linked to PLCγ1 or PLCγ2 dysfunction may not benefit from this research.
What this research studies
This research focuses on discovering selective inhibitors for two enzymes, PLCγ1 and PLCγ2, which are linked to cancer development. The team has developed a novel fluorescent substrate that allows for high-throughput screening of a large library of compounds to find potential inhibitors. By testing 200,000 compounds, they aim to identify those that effectively inhibit these enzymes, which could lead to new cancer therapies. The approach combines advanced biochemical techniques with innovative chemical synthesis to enhance the screening process.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for various cancers, improving treatment options for patients.
How similar studies have gone: While the specific inhibitors for PLCγ1 and PLCγ2 are novel, similar approaches in targeting other enzymes have shown promise in cancer treatment.
Where this research is happening
-
Purdue University
West Lafayette, United States Active
Researchers
- Principal investigator: Zhang, Zhong-Yin — Purdue University
- Study coordinator: Zhang, Zhong-Yin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.